S Biomedics Co., Ltd. (304360) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for S Biomedics Co., Ltd. (304360:KRX), powered by AI.

Current Price
₩34,100
P/E Ratio
-52.0
Market Cap
422.3B
Sector
Healthcare
What is the S Biomedics Co., Ltd. stock price forecast?

S Biomedics Co., Ltd. is currently trading at ₩34,100. View real-time AI analysis on Alpha Lenz.

What is S Biomedics Co., Ltd. insider trading activity?

View the latest insider trading data for S Biomedics Co., Ltd. on Alpha Lenz.

What is S Biomedics Co., Ltd.'s P/E ratio?

S Biomedics Co., Ltd.'s P/E ratio is -52.0.

S Biomedics Co., Ltd.

KRX · 304360
₩34,100+5,600(+19.65%)Market closedKRX regular session 09:00–15:30 KST
Ask about S Biomedics Co., Ltd.'s future dividend policy...
Alpha Chat Insight

S Biomedics Co., Ltd. trades at a P/E of -52.0 (undervalued) with modest ROE of -79.1%. 3Y revenue CAGR of 11.0% highlights clear growth momentum.

Ask for details

Company Overview

S Biomedics Co., Ltd. is a biotechnology company engaged in the research and development of cutting-edge biomedical products. The primary focus of S Biomedics is on creating innovative solutions within the field of regenerative medicine. This involves the production of advanced therapeutic products, including stem cell-based therapies, aiming to address substantial medical needs in regenerative treatment areas. The company's research and technological advancements have the potential to significantly impact the healthcare and life sciences industries, particularly in improving patient outcomes through advanced medical treatments. S Biomedics seeks to leverage its expertise in biomedicine to contribute meaningfully to the medical sector by providing state-of-the-art products designed to repair and regenerate damaged tissues. Serving both domestic and international markets, the company positions itself at the forefront of biotechnological innovation, emphasizing rigorous R&D and a commitment to pushing the boundaries of medical science. Its role in the financial market reflects the growing interest and investment in the biotechnological sector, driven by the promise of transformative healthcare solutions.

CEO강세일
SectorHealthcare
IndustryBiotechnology
Employees52

Company Statistics

FY 2025

Profile

₩422,332,864,800Market Cap
₩16,547,626,700Revenue
12.39MShares Out
52Employees

Margins

45.61%Gross
-35.60%EBITDA
-50.42%Operating
-41.15%Pre-Tax
-42.66%Net

Valuation

-52.00P/E
48.68P/B
25.52EV/Sales
-74.09EV/EBITDA
-50.49P/FCF

Growth (CAGR)

10.96%Rev 3Yr
25.48%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-16.45%ROA
-79.08%ROE
-12.49%ROIC

Financial Health

₩6,085,001,720Cash & Cash Equivalents
₩18,408,494,620Net Debt
146.45%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

S Biomedics Co., Ltd. (ticker: 304360) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 52 employees. Market cap is $422.3B.

The current price is ₩34,100 with a P/E ratio of -52x and P/B of 48.68x.

ROE is -79.08% and operating margin is -50.42%. Annual revenue is $16.5B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
S Biomedics Co., Ltd. (304360) Stock Forecast 2026 ₩34,100 — Price, Financials & Analyst Targets | Alpha Lenz